## TABLE 1: TNF superfamily Ligands 

<table style="width:100%;">
<colgroup>
<col style="width: 4%" />
<col style="width: 7%" />
<col style="width: 10%" />
<col style="width: 5%" />
<col style="width: 10%" />
<col style="width: 9%" />
<col style="width: 4%" />
<col style="width: 12%" />
<col style="width: 11%" />
<col style="width: 12%" />
<col style="width: 11%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>LocusLink ID</strong></td>
<td><h2 id="symbol">Symbol</h2></td>
<td><blockquote>
<p><strong>Common name</strong></p>
</blockquote></td>
<td><strong>Position</strong></td>
<td><p id="aliases" class="heading">Aliases</p></td>
<td><blockquote>
<p><strong>Binds to Receptor(s)</strong></p>
</blockquote></td>
<td><strong>OMIM ID</strong></td>
<td><h1 id="key-functions">Key Functions</h1></td>
<td><blockquote>
<p><strong>Phenotype associated with overexpression</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Phenotype associated with deficiency</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Human Genetic Diseases</strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>4049</strong></td>
<td><strong>TNFSF1</strong></td>
<td><blockquote>
<p><strong>Lymphotoxin alpha (Ltα)</strong></p>
</blockquote></td>
<td><strong>6p21.3</strong></td>
<td><blockquote>
<p><strong>LT, TNFB, TNFSF1</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TNFR2 (1B), TNFR1 (1A), HVEM (14)</strong></p>
</blockquote></td>
<td><strong>153440</strong></td>
<td><blockquote>
<p><strong>lymphoid organ formation</strong></p>
</blockquote></td>
<td></td>
<td><blockquote>
<p><strong>Absence of LN and PP, defective GC formation</strong></p>
</blockquote></td>
<td></td>
</tr>
<tr class="odd">
<td><strong>7124</strong></td>
<td><strong>TNFSF2</strong></td>
<td><blockquote>
<p><strong>tumor necrosis factor (TNF)</strong></p>
</blockquote></td>
<td><strong>6p21.3</strong></td>
<td><blockquote>
<p><strong>DIF, TNFA, TNFSF2, CACHECTIN</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TNFR2 (1B), TNFR1 (1A)</strong></p>
</blockquote></td>
<td><strong>191160</strong></td>
<td><blockquote>
<p><strong>inflammation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Wasting syndrome, arthritis</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>defective GC formation, resistance to endotoxic shock and
experimental arthritis</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TNF2 (G-308A) promotor polymorphism associated with increased
susceptability to septic shock. asthma and RA severity</strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>4050</strong></td>
<td><strong>TNFSF3</strong></td>
<td><blockquote>
<p><strong>lymphotoxin beta (LTβ)</strong></p>
</blockquote></td>
<td><strong>6p21.3</strong></td>
<td><blockquote>
<p><strong>p33, TNFC, TNFSF3</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>as a β2α1 heterotrimer with LT-α binds to LT-β Receptor
(3)</strong></p>
</blockquote></td>
<td><strong>600978</strong></td>
<td><blockquote>
<p><strong>lymphoid organ formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Ectopic lymphoid organ formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>7292</strong></td>
<td><strong>TNFSF4</strong></td>
<td><blockquote>
<p><strong>OX40 Ligand</strong></p>
</blockquote></td>
<td><strong>1q25</strong></td>
<td><blockquote>
<p><strong>GP34, OX4OL, TXGP1, CD134L, OX-40L</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>OX40 (4)</strong></p>
</blockquote></td>
<td><strong>603594</strong></td>
<td><blockquote>
<p><strong>CD4 T cell expansion, survival, and Th2
development</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Increased Th2 responses</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Th2 deficiency, blockade improves EAE</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>959</strong></td>
<td><strong>TNFSF5</strong></td>
<td><blockquote>
<p><strong>CD40 Ligand</strong></p>
</blockquote></td>
<td><strong>Xq26</strong></td>
<td><blockquote>
<p><strong>IGM, IMD3, TRAP, gp39, CD154, CD40L, HIGM1,
T-BAM,</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>CD40 (5)</strong></p>
</blockquote></td>
<td><strong>300386</strong></td>
<td><blockquote>
<p><strong>Costimulation and differentiation of B cells and
APC</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Constitutive expression in B cells or keratinocytes leads to
SLE-like syndrome</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Immunodeficiency due to Defective Ig class switching and
germinal center formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>X-linked hyper-IGM syndrome associated with CD40L loss of
function mutations</strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>356</strong></td>
<td><strong>TNFSF6</strong></td>
<td><blockquote>
<p><strong>Fas Ligand</strong></p>
</blockquote></td>
<td><strong>1q23</strong></td>
<td><blockquote>
<p><strong>FASL, CD178, CD95L, APT1LG1</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Fas (6), DcR3 (6B)</strong></p>
</blockquote></td>
<td><strong>134638</strong></td>
<td><blockquote>
<p><strong>Mediator of CD4(+) T cell apoptosis due to restimulation and
apoptosis in other cell types</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Lymphadenopathy and Systemic Autoimmunity</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Autoimmune Lymphoproliferative Syndrome (ALPS) type
Ib</strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>970</strong></td>
<td><strong>TNFSF7</strong></td>
<td><blockquote>
<p><strong>CD27 Ligand</strong></p>
</blockquote></td>
<td><strong>19p13</strong></td>
<td><blockquote>
<p><strong>CD70, CD27L, CD27LG</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>CD27 (7)</strong></p>
</blockquote></td>
<td><strong>602840</strong></td>
<td><blockquote>
<p><strong>T cell costimulation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>T cell hyperactivation eventually leading to immunodeficiency
(HIV-like)</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>944</strong></td>
<td><strong>TNFSF8</strong></td>
<td><blockquote>
<p><strong>CD30 Ligand</strong></p>
</blockquote></td>
<td><strong>9q33</strong></td>
<td><blockquote>
<p><strong>CD153, CD30L, CD30LG</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>CD30 (8)</strong></p>
</blockquote></td>
<td><strong>603875</strong></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8744</strong></td>
<td><strong>TNFSF9</strong></td>
<td><blockquote>
<p><strong>4-1-BB Ligand</strong></p>
</blockquote></td>
<td><strong>19p13.3</strong></td>
<td><blockquote>
<p><strong>4-1BB-L</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>4-1BB (9)</strong></p>
</blockquote></td>
<td><strong>606182</strong></td>
<td><blockquote>
<p><strong>T cell costimulation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>8743</strong></td>
<td><strong>TNFSF10</strong></td>
<td><blockquote>
<p><strong>(TNF-like apoptosis inducing ligand)TRAIL</strong></p>
</blockquote></td>
<td><strong>3q26</strong></td>
<td><blockquote>
<p><strong>TL2, APO2L, TRAIL, Apo-2L</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>DR4 (10A), DR5 (10B), DcR1 (10C), DcR2 (10D)</strong></p>
</blockquote></td>
<td><strong>603598</strong></td>
<td><blockquote>
<p><strong>Dendritic cell apoptosis, NK-cell mediated tumor cell
killing</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>defective NK-mediated tumor eradication</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8600</strong></td>
<td><strong>TNFSF11</strong></td>
<td><blockquote>
<p><strong>RANK-L</strong></p>
</blockquote></td>
<td><strong>13q14</strong></td>
<td><blockquote>
<p><strong>ODF, OPGL, sOdf, RANKL, TRANCE, hRANKL2</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>RANK (11A)</strong></p>
</blockquote></td>
<td><strong>602642</strong></td>
<td><blockquote>
<p><strong>mediates osteoclast formation and bone remodeling.
Stimulation of APC</strong></p>
</blockquote></td>
<td><blockquote>
<p> </p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>8742</strong></td>
<td><strong>TNFSF12</strong></td>
<td><blockquote>
<p><strong>TWEAK</strong></p>
</blockquote></td>
<td><strong>17p13</strong></td>
<td><blockquote>
<p><strong>APO3L, DR3LG, TWEAK, MGC20669</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TWEAK-R (12A)</strong></p>
</blockquote></td>
<td><strong>602695</strong></td>
<td><blockquote>
<p><strong> Potential role in inflammation and lymphocyte
function</strong></p>
</blockquote></td>
<td></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8741</strong></td>
<td><strong>TNFSF13</strong></td>
<td><blockquote>
<p><strong>APRIL</strong></p>
</blockquote></td>
<td><strong>17p13.1</strong></td>
<td><blockquote>
<p><strong>APRIL, TALL2, TWE-PRIL</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TACI (13B), BCMA (17)</strong></p>
</blockquote></td>
<td><strong>604472</strong></td>
<td><blockquote>
<p><strong>Promotes T-independent type-2 responses through interactions
with TACI</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>overexpression in T cells produces prolonged T cell survival
and enhanced TI-2 responses</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>10673</strong></td>
<td><strong>TNFSF13B</strong></td>
<td><blockquote>
<p><strong>BlyS, BAFF</strong></p>
</blockquote></td>
<td><strong>13q32-34</strong></td>
<td><blockquote>
<p><strong>BAFF, BLYS, TALL1, THANK, ZTNF4</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TACI (3B), BAFF-R (13C), BCMA(17),</strong></p>
</blockquote></td>
<td><strong>603969</strong></td>
<td><blockquote>
<p><strong>promotes B cell maturation, plasmablast survival</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>SLE-like systemic autoimmunity and arthritis</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8740</strong></td>
<td><strong>TNFSF14</strong></td>
<td><blockquote>
<p><strong>LIGHT</strong></p>
</blockquote></td>
<td><strong>19p13.3</strong></td>
<td><blockquote>
<p><strong>LTg, TR2, HVEML, LIGHT</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>HVEM (14), LT-βR (3), DcR3 (6B)</strong></p>
</blockquote></td>
<td><strong>604520</strong></td>
<td><blockquote>
<p><strong>CD8 T cell and APC costimulation,</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>inflammation, T cell hyperactivation Th1 bias</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>defective CD8 T cell costimulation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>9966</strong></td>
<td><strong>TNFSF15</strong></td>
<td><blockquote>
<p><strong>TL1A</strong></p>
</blockquote></td>
<td><strong>9q32</strong></td>
<td><blockquote>
<p><strong>TL1, TL1A, VEGI</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>DR3 (25)</strong></p>
</blockquote></td>
<td><strong>604052</strong></td>
<td><blockquote>
<p><strong>Recently identified ligand for DR3 (TNFRSF25)</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Blockade impairs T</strong></p>
<p><strong>Cell-mediated immunopathology</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8995</strong></td>
<td><strong>TNFSF18</strong></td>
<td><blockquote>
<p><strong>GITR Ligand</strong></p>
</blockquote></td>
<td><strong>1q23</strong></td>
<td><blockquote>
<p><strong>TL6, AITRL, GITRL, hGITRL</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>GITR (18)</strong></p>
</blockquote></td>
<td><strong>603898</strong></td>
<td><blockquote>
<p><strong>T cell costimulation (+)CD25(+) regulatory T
cells</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>1896</strong></td>
<td><strong>ED1</strong></td>
<td><blockquote>
<p><strong>ectodermal dysplasia 1, anhidrotic (EDA1)</strong></p>
</blockquote></td>
<td><strong>X</strong></td>
<td><blockquote>
<p><strong>EDA, HED, EDA1, XHED, XLHED</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>EDAR</strong></p>
</blockquote></td>
<td><strong>305100</strong></td>
<td><blockquote>
<p><strong>Tooth, hair and Sweat gland formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>X-LINKED ECTODERMAL DYSPLASIA</strong></p>
</blockquote></td>
</tr>
</tbody>
</table>

## TABLE 2: TNF superfamily Receptors

<table>
<colgroup>
<col style="width: 5%" />
<col style="width: 9%" />
<col style="width: 10%" />
<col style="width: 9%" />
<col style="width: 9%" />
<col style="width: 8%" />
<col style="width: 5%" />
<col style="width: 11%" />
<col style="width: 12%" />
<col style="width: 16%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>LocusLink ID</strong></td>
<td><h3 id="symbol-1">Symbol</h3></td>
<td><blockquote>
<p><strong>Common Name(s)</strong></p>
</blockquote></td>
<td><h3 id="position">Position</h3></td>
<td><p id="aliases-1" class="heading">Aliases</p></td>
<td><blockquote>
<p><strong>Binds to Ligand(s)</strong></p>
</blockquote></td>
<td><h4 id="omim">OMIM </h4>
<h4 id="id">ID</h4></td>
<td><p id="key-functions-1" class="heading">Key Functions</p></td>
<td><blockquote>
<p><strong>Phenotype associated with deficiency</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Human Genetic Diseases</strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>7132</strong></td>
<td><h5 id="tnfrsf1a">TNFRSF1A</h5></td>
<td><blockquote>
<p><em><strong>tumor necrosis factor receptor 1
(TNF-R1)</strong></em></p>
</blockquote></td>
<td><strong>12p13.2</strong></td>
<td><blockquote>
<p><strong>FPF, p55, p60, TBP1, TNF-R, TNFAR, TNFR1, p55-R, CD120a,
TNFR55, TNFR60, TNF-R-I, TNF-R55, MGC19588</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TNFα (2), Ltα (1)</strong></p>
</blockquote></td>
<td><strong>191190</strong></td>
<td><blockquote>
<p><strong>Mediates TNF-induced inflammation (and apoptosis in some
cells)</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>resistance to TNF-induced artrhritis models, resistant to
endotoxic shock, Increased sensitivity to bacterial
pathogens</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Periodic fever syndrome(TRAPS)associated with heterozygous
extracellular mutaions</strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>7133</strong></td>
<td><strong>TNFRSF1B</strong></td>
<td><blockquote>
<p><strong>tumor necrosis factor receptor 2 (TNF-R2)</strong></p>
</blockquote></td>
<td><strong>1p36.3-p36.2</strong></td>
<td><blockquote>
<p><strong>p75, TBPII, TNFBR, TNFR2, CD120b, TNFR80, TNF-R75, p75TNFR,
TNF-R-II</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TNFα (2), Ltα (1)</strong></p>
</blockquote></td>
<td><strong>191191</strong></td>
<td><blockquote>
<p><strong>May enhance pro-apoptotic effect of TNFR1</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>still susceptible to TNF-induced arthritis models, defective
CD8(+) T cell apoptosis after restimulation, Increased sensitivity to
bacterial pathogens</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>4055</strong></td>
<td><strong>TNFRSF3</strong></td>
<td><blockquote>
<p><strong>lymphotoxin beta receptor</strong></p>
</blockquote></td>
<td><strong>12p13</strong></td>
<td><blockquote>
<p><strong>LTBR, CD18, TNFCR, TNFR-RP, TNFRSF3, TNFR2-RP, LT-BETA-R,
TNF-R-III</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>LIGHT (14), LTβ (3)</strong></p>
</blockquote></td>
<td><strong>600979</strong></td>
<td><blockquote>
<p><strong>lymphoid organ formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>No LN, PP, defective GC formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>7293</strong></td>
<td><strong>TNFRSF4</strong></td>
<td><blockquote>
<p><strong>OX40</strong></p>
</blockquote></td>
<td><strong>1p36</strong></td>
<td><blockquote>
<p><strong>OX40, ACT35, CD134, TXGP1L</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>OX40L (4)</strong></p>
</blockquote></td>
<td><strong>600315</strong></td>
<td><blockquote>
<p><strong>T cell costimulation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Defective CD4 T cell responses</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>958</strong></td>
<td><strong>TNFRSF5</strong></td>
<td><blockquote>
<p><strong>CD40</strong></p>
</blockquote></td>
<td><strong>20q12-q13.2</strong></td>
<td><blockquote>
<p><strong>p50, Bp50, CD40, CDW40, MGC9013</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>CD40L (5)</strong></p>
</blockquote></td>
<td><strong>109535</strong></td>
<td><blockquote>
<p><strong>Costimulation and differentiation of B cells and
APC</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Defective Ig class switching and germinal center
formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Autosomal hyper-IgM syndrome associated with loss-of function
mutations</strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><em><strong>355</strong></em></td>
<td><em><strong>TNFRSF6</strong></em></td>
<td><blockquote>
<p><em><strong>Fas, CD95</strong></em></p>
</blockquote></td>
<td><strong>10q24.1</strong></td>
<td><blockquote>
<p><strong>FAS, APT1, CD95, APO-1</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>FasL (6)</strong></p>
</blockquote></td>
<td><strong>134637</strong></td>
<td><blockquote>
<p><strong>Apoptosis of restimulated CD4 T cells, B cells,
?others</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Defective apoptosis of restimulated CD4(+) T
cells</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Autoimmune Lymphoproliferative Syndrome (ALPS) associated
with heterozygous dominat-interfering mutations</strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8771</strong></td>
<td><strong>TNFRSF6B</strong></td>
<td><blockquote>
<p><strong>Decoy Receptor 3</strong></p>
</blockquote></td>
<td><strong>20q13.3</strong></td>
<td><blockquote>
<p><strong>M68, TR6, DCR3, DJ583P15.1.1</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>FasL (6), TL1A (15), LIGHT (14)</strong></p>
</blockquote></td>
<td><strong>603361</strong></td>
<td><blockquote>
<p><strong>Soluble decoy receptor for FasL, LIGHT, and TL1A. May have a
role in tumor immune evasion</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>939</strong></td>
<td><strong>TNFRSF7</strong></td>
<td><blockquote>
<p><strong>CD27</strong></p>
</blockquote></td>
<td><strong>12p13</strong></td>
<td><blockquote>
<p><strong>T14, CD27, S152, Tp55, MGC20393</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>CD27L (7)</strong></p>
</blockquote></td>
<td><strong>186711</strong></td>
<td><blockquote>
<p><strong>T cell costimulation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Defective T cell responses</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>943</strong></td>
<td><strong>TNFRSF8</strong></td>
<td><blockquote>
<p><strong>CD30</strong></p>
</blockquote></td>
<td><strong>1p36</strong></td>
<td><blockquote>
<p><strong>CD30, KI-1, D1S166E</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>CD30L (8)</strong></p>
</blockquote></td>
<td><strong>153243</strong></td>
<td><blockquote>
<p><strong>? Inhibition of CD8 T cell effector function</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>3604</strong></td>
<td><strong>TNFRSF9</strong></td>
<td><blockquote>
<p><strong>4-1BB, CD137</strong></p>
</blockquote></td>
<td><strong>1p36</strong></td>
<td><blockquote>
<p><strong>ILA, 4-1BB, CD137, CDw137, MGC2172</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>4-1BBL (9)</strong></p>
</blockquote></td>
<td><strong>602250</strong></td>
<td><blockquote>
<p><strong>T cell costimulation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Defective CD8 T cell responses</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><em><strong>8797</strong></em></td>
<td><em><strong>TNFRSF10A</strong></em></td>
<td><blockquote>
<p><em><strong>Death Receptor 4 (DR4)</strong></em></p>
</blockquote></td>
<td><strong>8p21</strong></td>
<td><blockquote>
<p><strong>DR4, APO2, MGC9365, TRAILR1, TRAILR-1</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TRAIL (10)</strong></p>
</blockquote></td>
<td><strong>603611</strong></td>
<td><blockquote>
<p><strong>Mediator of dendritic cell and tumor cell
apoptosis</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><em><strong>8795</strong></em></td>
<td><em><strong>TNFRFRSF10B</strong></em></td>
<td><blockquote>
<p><em><strong>Death Receptor 5 (DR5)</strong></em></p>
</blockquote></td>
<td><strong>8p22-p21</strong></td>
<td><blockquote>
<p><strong>DR5, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A,
TRICK2B, TRAIL-R2, KILLER/DR5</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TRAIL (10)</strong></p>
</blockquote></td>
<td><strong>603612</strong></td>
<td><blockquote>
<p><strong>Mediator of dendritic cell and tumor cell
apoptosis</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8794</strong></td>
<td><strong>TNFRSF10C</strong></td>
<td><blockquote>
<p><strong>Decoy Receptor 1</strong></p>
</blockquote></td>
<td><strong>8p22-p21</strong></td>
<td><blockquote>
<p><strong>LIT, DCR1, TRID, TRAILR3</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TRAIL (10)</strong></p>
</blockquote></td>
<td><strong>603613</strong></td>
<td><blockquote>
<p><strong>GPI-linked Decoy receptor, interferes with TRAIL
function</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>8793</strong></td>
<td><strong>TNFRSF10D</strong></td>
<td><blockquote>
<p><strong>Decoy Receptor 2</strong></p>
</blockquote></td>
<td><strong>8p21</strong></td>
<td><blockquote>
<p><strong>DCR2, TRUNDD, TRAILR4</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TRAIL (10)</strong></p>
</blockquote></td>
<td><strong>603614</strong></td>
<td><blockquote>
<p><strong>Transmembrane decoy receptor, interferes with TRAIL
function</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>8792</strong></td>
<td><strong>TNFRSF11A</strong></td>
<td><blockquote>
<p><strong>(Receptor activator of NF-kappa B) RANK</strong></p>
</blockquote></td>
<td><strong>18q22.1</strong></td>
<td><blockquote>
<p><strong>OFE, ODFR, PDB2, RANK, TRANCER</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>RANKL (11)</strong></p>
</blockquote></td>
<td><strong>603499</strong></td>
<td><blockquote>
<p><strong>mediates DC costimulation and osteoclast maturation and
activation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Osteopetrosis due to osteoclast deficiency, no lymph nodes,
impaired B cell development</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>4982</strong></td>
<td><strong>TNFRSF11B</strong></td>
<td><blockquote>
<p><strong>Osteoprotegerin (OPG)</strong></p>
</blockquote></td>
<td><strong>8q24</strong></td>
<td><blockquote>
<p><strong>OPG, TR1, OCIF, MGC29565</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TRAIL (10), RANKL (11)</strong></p>
</blockquote></td>
<td><strong>602643</strong></td>
<td><blockquote>
<p><strong>Soluble decoy receptor for RANK</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>osteoporosis, arterial calcification</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="even">
<td><strong>51330</strong></td>
<td><strong>TNFRSF12A</strong></td>
<td><blockquote>
<p><strong>TWEAK-receptor</strong></p>
</blockquote></td>
<td><strong>16p13.3</strong></td>
<td><blockquote>
<p><strong>FN14, TWEAKR</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>TWEAK (12)</strong></p>
</blockquote></td>
<td><strong>605914</strong></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
<tr class="odd">
<td><strong>8791</strong></td>
<td><strong>TNFRSF12L</strong></td>
<td><blockquote>
<p><strong>tumor necrosis factor receptor superfamily, member
12-like</strong></p>
</blockquote></td>
<td><strong>1p36.2</strong></td>
<td><blockquote>
<p><strong>DR3-Like</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>T cell hyperactivation, increased susceptibility to
restimulation-induced apoptosis</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
</tr>
</tbody>
</table>

## 

## TABLE 2: TNF superfamily Receptors, continued

<table>
<colgroup>
<col style="width: 5%" />
<col style="width: 7%" />
<col style="width: 13%" />
<col style="width: 9%" />
<col style="width: 9%" />
<col style="width: 8%" />
<col style="width: 5%" />
<col style="width: 9%" />
<col style="width: 14%" />
<col style="width: 17%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>LocusLink ID</strong></td>
<td><h3 id="symbol-2">Symbol</h3></td>
<td><blockquote>
<p><strong>Common Name(s)</strong></p>
</blockquote></td>
<td><h3 id="position-1">Position</h3></td>
<td><blockquote>
<p><strong>Aliases</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Binds to Ligand(s)</strong></p>
</blockquote></td>
<td><h4 id="omim-1">OMIM</h4>
<h4 id="id-1"> ID</h4></td>
<td><blockquote>
<p><strong>Key Functions</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Phenotype associated with deficiency</strong></p>
</blockquote></td>
<td><strong>Human Genetic Diseases</strong></td>
</tr>
<tr class="even">
<td><strong>23495</strong></td>
<td><strong>TNFRSF13B</strong></td>
<td><blockquote>
<p><strong>TACI</strong></p>
</blockquote></td>
<td><strong>17p11.2</strong></td>
<td><blockquote>
<p><strong>TACI</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>APRIL (13), BAFF (13B)</strong></p>
</blockquote></td>
<td><strong>604907</strong></td>
<td><blockquote>
<p><strong>May inhibit some of the pro-survival effects of
BAFF-R</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Decreased TI-2 B cell responses, but B cell hyperplasia and
autoimmunity</strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="odd">
<td><strong>115650</strong></td>
<td><strong>TNFRSF13C</strong></td>
<td><blockquote>
<p><strong>BAFF receptor (BAFF-R)</strong></p>
</blockquote></td>
<td><strong>22q13.1-q13.31</strong></td>
<td><blockquote>
<p><strong>BAFF/BLyS receptor 3</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>BAFF (13B)</strong></p>
</blockquote></td>
<td><strong>606269</strong></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Impaired survival of immature transitional B
cells</strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="even">
<td><strong>8764</strong></td>
<td><strong>TNFRSF14</strong></td>
<td><blockquote>
<p><strong>Herpes Virus Entry Mediator (HVEM)</strong></p>
</blockquote></td>
<td><strong>1p36.3-p36.2</strong></td>
<td><blockquote>
<p><strong>TR2, ATAR, HVEA, HVEM, LIGHTR</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>LIGHT (14), Herpesviruses</strong></p>
</blockquote></td>
<td><strong>602746</strong></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="odd">
<td><strong>4804</strong></td>
<td><strong>TNFRSF16</strong></td>
<td><blockquote>
<p><strong>NGF-R</strong></p>
</blockquote></td>
<td><strong>17q21-q22</strong></td>
<td><blockquote>
<p><strong>TNFRSF16, p75(NTR)</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>NGF (not a TNF family member)</strong></p>
</blockquote></td>
<td><strong>162010</strong></td>
<td><blockquote>
<p><strong>NGF receptor - evolutionary outlier as NGF not classical TNF
family molecule</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>Defective sensory neuron innervation; impaired heat
sensitivity</strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="even">
<td><strong>608</strong></td>
<td><strong>TNFRSF17</strong></td>
<td><blockquote>
<p><strong>B cell maturation antigen (BCMA)</strong></p>
</blockquote></td>
<td><strong>16p13.1</strong></td>
<td><blockquote>
<p><strong>BCM</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>APRIL (13), BAFF (13B)</strong></p>
</blockquote></td>
<td><strong>109545</strong></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>apparently no B cell phenotype</strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="odd">
<td><strong>8784</strong></td>
<td><strong>TNFRSF18</strong></td>
<td><blockquote>
<p><strong>Glucocorticoid-induced TNF receptor (GITR)</strong></p>
</blockquote></td>
<td><strong>1p36.3</strong></td>
<td><blockquote>
<p><strong>AITR, GITR, GITR-D</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>GITRL (18)</strong></p>
</blockquote></td>
<td><strong>603905</strong></td>
<td><blockquote>
<p><strong>T cell costimulation, marker for CD4(+)CD25(+) Treg cells,
modulates Treg function</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>T cell hyperactivation</strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="even">
<td><strong>55504</strong></td>
<td><strong>TNFRSF19</strong></td>
<td><blockquote>
<p><strong>Toxicity and JNK inducer (TAJ)</strong></p>
</blockquote></td>
<td><strong>13q12.11-q12.3</strong></td>
<td><blockquote>
<p><strong>TROY, TRADE, TAJ-alpha</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong>606122</strong></td>
<td><blockquote>
<p><strong>similar to EDAR, expressed in skin and brain</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="odd">
<td><strong>84957</strong></td>
<td><strong>TNFRSF19L</strong></td>
<td><blockquote>
<p><strong>RELT</strong></p>
</blockquote></td>
<td><strong>11q13.3</strong></td>
<td><blockquote>
<p><strong>RELT, FLJ14993</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td></td>
<td><blockquote>
<p><strong>possible T cell costimulator</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="even">
<td><em><strong>27242</strong></em></td>
<td><h3 id="tnfrsf21"><em>TNFRSF21</em></h3></td>
<td><blockquote>
<p><em><strong>Death Receptor 6 (DR6)</strong></em></p>
</blockquote></td>
<td><strong>6p21.1-12.2</strong></td>
<td><blockquote>
<p><strong>DR6, BM-018</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong>605732</strong></td>
<td><blockquote>
<p><strong>negative regulator B and T cell responses</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>enhanced T and B cell activation</strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="odd">
<td><strong>94098</strong></td>
<td><strong>TNFRSF22</strong></td>
<td><blockquote>
<p><strong>tumor necrosis factor receptor superfamily, member
22</strong></p>
</blockquote></td>
<td><strong>11p15.5</strong></td>
<td><blockquote>
<p><strong>SOBa, Tnfrh2, 2810028K06Rik</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="even">
<td><strong>94099</strong></td>
<td><strong>TNFRSF23</strong></td>
<td><blockquote>
<p><strong>tumor necrosis factor receptor superfamily, member
23</strong></p>
</blockquote></td>
<td><strong>11p15.5</strong></td>
<td><blockquote>
<p><strong>mSOB, Tnfrh1</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
<tr class="odd">
<td><em><strong>8718</strong></em></td>
<td><em><strong>TNFRSF25</strong></em></td>
<td><blockquote>
<p><em><strong>Death Receptor 3 (DR3)</strong></em></p>
</blockquote></td>
<td><em><strong>1p36.2</strong></em></td>
<td><blockquote>
<p><em><strong>DR3, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, WSL-LR,
TNFRSF12</strong></em></p>
</blockquote></td>
<td><blockquote>
<p><em><strong>TL1A (15)</strong></em></p>
</blockquote></td>
<td><em><strong>603366</strong></em></td>
<td><blockquote>
<p><em><strong> </strong></em></p>
</blockquote></td>
<td><blockquote>
<p><em><strong>?impaired thymic negative selection</strong></em></p>
</blockquote></td>
<td><em><strong> </strong></em></td>
</tr>
<tr class="even">
<td><strong>10913</strong></td>
<td><em><strong>EDAR</strong></em></td>
<td><blockquote>
<p><em><strong>ectodysplasin 1, anhidrotic receptor</strong></em></p>
</blockquote></td>
<td><strong>2q11-q13</strong></td>
<td><blockquote>
<p><strong>DL, ED3, ED5, ED1R, EDA3, EDA-A1R</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>E1</strong></p>
</blockquote></td>
<td><strong>604095</strong></td>
<td><blockquote>
<p><strong>tooth, hair, sweat gland formation</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>abnormal tooth, hair, and sweat gland formation</strong></p>
</blockquote></td>
<td><strong>Ectodermal Dysplasia</strong></td>
</tr>
<tr class="odd">
<td><strong>60401</strong></td>
<td><strong>XEDAR</strong></td>
<td><blockquote>
<p><strong>XEDAR: ectodysplasin A2 isoform receptor</strong></p>
</blockquote></td>
<td><strong>Xq12</strong></td>
<td><blockquote>
<p><strong>EDAA2R, EDA-A2R</strong></p>
</blockquote></td>
<td><blockquote>
<p><strong>EDA-A2</strong></p>
</blockquote></td>
<td><strong>300276</strong></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><blockquote>
<p><strong> </strong></p>
</blockquote></td>
<td><strong> </strong></td>
</tr>
</tbody>
</table>

**KEY**

###### Receptors in italics have a C-terminal Death Domain

**Locuslink ID: Gene "homepage" curated by NCBI. Go To
<http://www.ncbi.nlm.nih.gov/LocusLink/> and type the locuslink ID in
the search window**

**OMIM: ID in the Online Mendelian Inheritance in Man Database. Go to
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM> and type in the
OMIM ID in the search window**

**Abbreviations: LN: Lymph Node, PP: Peyer's Patch, GC: Germinal
Center**